Pasithea Therapeutics 관리

관리 기준 확인 4/4

Pasithea Therapeutics CEO는 Tiago Marques, Aug2020 에 임명되었습니다 의 임기는 4.25 년입니다. 총 연간 보상은 $ 537.35K, 83.7% 로 구성됩니다. 83.7% 급여 및 16.3% 보너스(회사 주식 및 옵션 포함). 는 $ 120.38K 가치에 해당하는 회사 주식의 3.07% 직접 소유합니다. 120.38K. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 3.1 년입니다.

주요 정보

Tiago Marques

최고 경영자

US$537.3k

총 보상

CEO 급여 비율	83.7%
CEO 임기	4.3yrs
CEO 소유권	3.1%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06

CEO 보상 분석

Tiago Marques 의 보수는 Pasithea Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$16m
Jun 30 2024	n/a	n/a	-US$16m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$537k	US$450k	-US$16m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$539k	US$450k	-US$12m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$672k	US$244k	-US$2m

보상 대 시장: Tiago 의 총 보상 ($USD 537.35K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 650.80K ).

보상과 수익: Tiago 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Tiago Marques (47 yo)

4.3yrs

테뉴어

US$537,347

보상

Dr. Tiago Reis Marques, M. D., Ph. D., has been the Chief Executive Officer and Director at Pasithea Therapeutics Corp. since August 2020. He is a senior clinical fellow at Imperial College London and a le...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lawrence Steinman	Co-Founder	4.3yrs	US$250.00k	5.24% $ 205.7k
Tiago Marques	CEO & Director	4.3yrs	US$537.35k	3.07% $ 120.4k
Daniel Schneiderman	Chief Financial Officer	2.1yrs	US$345.94k	0% $ 0
Graeme Currie	Chief Development Officer	2.4yrs	US$444.86k	0% $ 0
Yassine Bendiabdallah	COO & Head of UK Clinics	3.7yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: KTTA 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lawrence Steinman	Co-Founder	4.3yrs	US$250.00k	5.24% $ 205.7k
Tiago Marques	CEO & Director	4.3yrs	US$537.35k	3.07% $ 120.4k
Alfred Novak	Independent Director	2.2yrs	US$50.00k	0.28% $ 10.9k
Emer Leahy	Independent Director	3.4yrs	US$60.00k	0% $ 0
Merit Cudkowicz	Member of Scientific Advisory Board	2.2yrs	데이터 없음	데이터 없음
Daniel Weinberger	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Luca Rastelli	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Simon Dumesnil	Independent Director	3.6yrs	US$60.00k	0.20% $ 7.8k
Rebecca Brown	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: KTTA 의 이사회는 경험(평균 재직 기간 3.1 년)으로 간주됩니다.

Pasithea Therapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024

Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023

High number of new and inexperienced directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

New major risk - Financial position

Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

New minor risk - Share price stability

Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients

New major risk - Financial position

Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate

Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023

High number of new and inexperienced directors

Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.

New major risk - Share price stability

Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.

Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea Therapeutics

Price target decreased to US$2.30

Less than half of directors are independent

Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp

Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek Therapeutics

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.

Camac Partners LLC Sends a Letter to Pasithea Therapeutics Corp

Less than half of directors are independent

Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of Directors

Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory Board

Camac Partners Provides Information to Shareholders of Pasithea Therapeutics

Camac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special Meeting

Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics Corp

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes Away

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory Board

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Pasithea Therapeutics Corp. announced that it has received $30.38 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in funding

Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.K

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령